CAMBRIDGE, Mass. - Eterna Therapeutics Inc. (NASDAQ:ERNA), a company focusing on mRNA cell engineering for new medicines, announced today the appointment of Peter Cicala to its Board of Directors. Cicala brings a wealth of experience in biotechnology and pharmaceutical intellectual property and strategic management to the team, with a background that spans start-ups to big pharma.
Sanjeev Luther, President and CEO of Eterna, expressed confidence in Cicala's ability to contribute to the company's growth, citing his deep industry experience. Cicala's professional background includes advising on drug development, strategic planning, and commercialization of therapeutics. His expertise also extends to patent litigation, prosecution, and regulatory matters in major pharmaceutical markets.
Cicala, who holds a JD (NASDAQ:JD) from Seton Hall University School of Law and a Bachelor of Science in Chemistry from Fairleigh Dickinson University, has over a decade of experience in medicinal chemistry. He has worked with several major pharmaceutical companies and universities on drug development programs.
The addition of Cicala to the board comes at a time when Eterna is advancing its portfolio of over 130 patents, which includes key mRNA cell engineering technologies. These technologies encompass mRNA cell reprogramming, mRNA gene editing, and the proprietary NoveSlice™, UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system.
Eterna's in-licensed technologies are central to its mission of transforming medicine through mRNA cell engineering. The company's strategic direction is focused on the development of next-generation therapies, and Cicala's appointment is poised to support this vision.
This news is based on a press release statement and provides an overview of the latest strategic move by Eterna Therapeutics, which is subject to the usual risks and uncertainties of the biotech industry. The company's progress and future plans are disclosed in its public filings with the U.S. Securities and Exchange Commission, including its Annual Report and subsequent Quarterly Reports.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.